Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To evaluate the response rate for patients with T-cell Non-Hodgkin's Lymphoma
(NHL)receiving the combination of vorinostat and bortezomib
2. To evaluate the safety and tolerability of the combination of vorinostat and bortezomib
in patients with relapsed or refractory T-cell NHL.
Secondary Objectives:
1. To assess overall survival and time to treatment failure in patients with T-cell NHL
treated with the combination of vorinostat and bortezomib.
2. Correlative studies will be done to assess the role of vorinostat mediated apoptosis
along with bortezomib synergy. Changes in marker expression from baseline to post
treatment will be correlated with patient clinical response.